vTv Therapeutics Drops as Diabetes Study Date Approaches
vTv Therapeutics shares fell 1.1% to $33.14 Friday afternoon, underperforming biotech indexes as investors await updates on its diabetes drug cadisegliatin. The company last reported on May 13, saying Phase 3 CATT1 enrollment remains on track for Q3 2026. Cash reserves rose to $98.1 million at March 31 after a $20 million licensing payment. No new filings or press releases have been issued since the quarterly report.